Advanced Melanoma

New research suggests gut bacteria may play a role in fatigue and pain experienced by melanoma patients receiving immunotherapy.

Learn about superficial spreading melanoma, from the ABCDE diagnostic rules to the latest in immunotherapy, targeted care and surgical options.

Diakonos Oncology receives FDA Fast Track status for DOC1021, a dendritic cell immunotherapy for patients with advanced or metastatic skin cancer.

A patient facing brain surgery finds comfort in "Grey's Anatomy" tropes and a surprise hospital dinner provided by her boyfriend's local restaurant.

Patients with advanced melanoma experienced high response rates when treated with commercial Amtagvi in a real-world clinical study.

The FDA cleared a phase 3 trial for iSCIB1+ after data showed 74% progression-free survival at 16 months for patients with advanced melanoma.

The FDA has granted orphan drug designation to IFx-2.0 for patients with stage 2B to stage 4 cutaneous melanoma.

Dr. Ariel Ostad explains how addressing uncertainty and scananxiety through communication and support can improve the cancer care experience for patients.

The FDA cleared a phase 3 trial of iSCIB1+ for advanced melanoma after phase 2 data showed improved progression free survival versus standard care.